Science Current Events | Science News | Brightsurf.com
 

Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC

April 04, 2012

CHICAGO - Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine. The findings were presented here at the AACR Annual Meeting 2012, held March 31 - April 4.

"This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer Center in La Jolla, Calif.

These findings represent an updated long-term survival analysis on patients treated with belagenpumatucel-L, a cell-based allogeneic vaccine derived from four lung cancer cell lines. The open-label study included 75 patients with non-small cell lung cancer (NSCLC) - two patients with stage 2 disease, 12 with stage 3A, 15 with stage 3B and 46 with stage 4. The researchers randomly assigned patients to three dose cohorts: 1.25, 2.5 or 5 × 107 cells/injection.

For all patients, median survival was 14.5 months, and the five-year survival rate was 20 percent. The 40 patients with stage 3B/4 cancer enrolled in the second and third dose cohorts had a median survival of 15.9 months and a one-year survival rate of 61 percent, a two-year survival rate of 41 percent and a five-year survival rate of 18 percent.

Patients with stage 3B/4 nonprogressive disease after chemotherapy had a median survival of 44.4 months; five-year survival was 50 percent, which is "unheard of for patients with NSCLC," Bazhenova said.

In contrast, patients who progressed after front-line chemotherapy had a median survival rate of 14.1 months and a 9.1 percent five-year survival rate.

Bazhenova said that although these results are intriguing, they must be confirmed in a phase III clinical trial, which is currently under way in eight countries.

American Association for Cancer Research


Related Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles


Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types
The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.

Preliminary results comparing PD-L1 IHC diagnostic assays in lung cancer released
A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the "BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT" at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19.

Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer (NSCLC) with a type of radiotherapy called stereotactic body radiation therapy (SBRT) is associated with a small but increased risk of death from causes other than cancer.

Plasma genotyping to predict treatment benefit in patients with NSCLC
The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.

New tool mines whole-exome sequencing data to match cancer with best drug
A University of Colorado Cancer study published today in the Journal of the American Medical Informatics Association (JAMIA) describes a new tool that interprets the raw data of whole exome tumor sequencing and then matches the cancer's unique genetics to FDA-approved targeted treatments.

Researchers identify potential targeted therapy for lung cancer using fly model
A drug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol-lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.

Improving access to clinical trials when biopsies are required
The requirement for tumor tissue specimens and associated analyses in order to participate in clinical trials appears to be a significant barrier to clinical trial enrollment and may delay treatment.

Three hits to fight lung cancer
Although the most common type of lung cancer - non-small cell lung cancer (NSCLC) - has recently seen major treatment advances in some genetic subtypes, other subtypes continue to evade effective treatment.

Non-small cell lung cancers can be sorted in clusters by endocytic changes
In the Age of Personalized Medicine, we've learned that one size doesn't fit all, least of all in cancer. Cancer is a disease of your cells, and sorting out your cancer from all others is a daunting challenge but one that cancer cell biologists are furiously pursuing.

Researchers identify biomarker of early lung cancer that may increase survival
Researchers in Taiwan have identified a biomarker that detects the most common lung cancer in its earliest stage. The discovery could one day change how long lung cancer patients live.
More Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles

NCCN Guidelines for Patients®: Non-Small Cell Lung Cancer

NCCN Guidelines for Patients®: Non-Small Cell Lung Cancer
by National Comprehensive Cancer Network® (NCCN®) (Author)


[OFFICIAL CURRENT VERSION] From the medical leaders of 27 of the world’s most renowned cancer centers united under the National Comprehensive Cancer Network® (NCCN®), comes this essential guide to non-small cell lung cancer. Adapted from clinical treatment guidelines used by physicians and oncology professionals around the world, these NCCN Guidelines for Patients® are packed with the latest information, treatment innovations, and resources about the diagnosis and treatment of lung cancer. Each patient-friendly chapter prepares patients and caregivers to talk with their doctors and make treatment decisions. Let this authoritative handbook be your guide! Part 1 – Lung cancer basics: Explains how lung cancer starts and how it spreads Part 2 – Assessing lung nodules: Discusses care...

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC


This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

Being Mortal: Medicine and What Matters in the End

Being Mortal: Medicine and What Matters in the End
by Atul Gawande (Author)



In Being Mortal, bestselling author Atul Gawande tackles the hardest challenge of his profession: how medicine can not only improve life but also the process of its ending

Medicine has triumphed in modern times, transforming birth, injury, and infectious disease from harrowing to manageable. But in the inevitable condition of aging and death, the goals of medicine seem too frequently to run counter to the interest of the human spirit. Nursing homes, preoccupied with safety, pin patients into railed beds and wheelchairs. Hospitals isolate the dying, checking for vital signs long after the goals of cure have become moot. Doctors, committed to extending life, continue to carry out devastating procedures that in the end extend suffering.Gawande, a practicing surgeon, addresses his...

OPDIVO (Nivolumab): Treats unresectable or Metastatic Melanoma (skin cancer) and Metastatic Squamous Non-Small Cell Lung Cancer

OPDIVO (Nivolumab): Treats unresectable or Metastatic Melanoma (skin cancer) and Metastatic Squamous Non-Small Cell Lung Cancer
by James Lee Anderson (Author)


“Although, your health condition may impact your everyday life, do not let it define who you are.” OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. OPDIVO (nivolumab) is also indicated for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. OPDIVO (nivolumab) treat your melanoma or lung cancer by working with your immune system. OPDIVO can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to...

Harrisons Manual of Medicine, 19th Edition

Harrisons Manual of Medicine, 19th Edition
by Dennis Kasper (Author), Anthony Fauci (Author), Stephen Hauser (Author), Dan Longo (Author), J. Jameson (Author), Joseph Loscalzo (Author)


Essential Clinical Information Drawn From Harrison’s Harrison’s Manual of Medicine is a concise, bedside resource derived from content found in Harrison’s Principles of Internal Medicine, Nineteenth Edition.  Perfect for use at the point of care, the Manual presents clinical information covering key aspects of the diagnosis, clinical manifestations, and treatment of the major diseases that are likely to be encountered in medical practice.Presented in full color and incorporating an efficient blend of succinct text, bullet points, algorithms, and tables Harrison’s Manual of Medicine, Nineteenth Edition covers every area of clinical medicine, including:·        Etiology and Epidemiology·        Clinically Relevant Pathophysiology·        Signs and...

Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine (Pocket Notebook)

Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine (Pocket Notebook)
by Marc S. Sabatine MD (Author)


Prepared by residents and attending physicians at Massachusetts General Hospital, the 5th edition of Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine provides key clinical information and solutions to common problems faced in the practice of internal medicine.Designed to fit in a pocket, this 6-ring looseleaf binder tackles the diagnosis and treatment of the most common disorders in cardiology, pulmonary medicine, gastroenterology, nephrology, hematology-oncology, infectious diseases, endocrinology, rheumatology, and neurology.Bulleted lists combined with tables and algorithms allow busy clinicians to find the information they need rapidly. A 16-page color insert displays classic normal and abnormal radiographs, CT scans, echocardiograms, peripheral blood...

A Preacher's Guide to Lectionary Sermon Series: Thematic Plans for Years A, B, and C

A Preacher's Guide to Lectionary Sermon Series: Thematic Plans for Years A, B, and C
by Amy K Butler (Foreword)


Preachers get the best of lectionary and topical series preaching with this comprehensive manual of sermon series ideas based on the Revised Common Lectionary. Designed to frame consecutive weeks of lectionary texts into seasonal and short-term series, a diverse group of twelve preachers outline multiple thematic series plans for each lectionary year. Each series plan provides a series overview, chart that outlines each segment of the series, tips and ideas, scriptural references, and a brief sermon starter. The series honors holy days and seasons and responds to typical patterns of church attendance, maximizing visitor retention and member engagement. Pastors can honor their commitment to lectionary preaching while taking advantage of the benefits series preaching can offer with this...

Lung Cancer

Lung Cancer
by Jack A. Roth (Editor), James D. Cox (Editor), Waun Ki Hong (Editor)


Lung cancer is a major cause of cancer-related deaths in men and women. However, since the first edition of Lung Cancer was published 14 years ago, rapid progress in the biology, prevention, diagnosis, and treatment of the disease has been made.

Davis's Drug Guide for Nurses

Davis's Drug Guide for Nurses
by April Hazard Vallerand PhD RN FAAN (Author), Cynthia A. Sanoski BS PharmD FCCP BCPS (Author)


SAFETY FIRST!

Davis’s Drug Guide for Nurses®, Fourteenth Edition delivers all of the information you need to administer medications safely across the lifespan—well-organized monographs for hundreds of generic and thousands of trade-name drugs.



BONUS!

FREE DIGITAL ACCESS

One-year subscription to DrugGuide.com, Davis’s Drug Guide Online, powered by Unbound Medicine. You’ll have access to over 1,100 monographs from your desktop, laptop, or any mobile device with a web browser.



LIFE-SAVING GUIDANCE…AT A GLANCE


Red tab for high alert medications, plus in-depth high alert and patient safety coverage
Red, CAPITALIZED letters for life-threatening side effects
Drug-drug,...

A Comprehensive Review For the Certification and Recertification Examinations for Physician Assistants

A Comprehensive Review For the Certification and Recertification Examinations for Physician Assistants
by Claire Babcock O'Connell MPH PA-C (Author)


The new, fifth edition of A Comprehensive Review for the Certification and Recertification Examinations for Physician Assistants is the foremost trusted preparation resource for the PANCE and PANRE. The text features high-yield outline-format review and pretest and post-test questions based on the blueprint of the National Commission on Certification of Physician Assistants (NCCPA). Developed and endorsed by the American Academy of Physician Assistants (AAPA) and the Physician Assistant Education Association (PAEA), this edition’s content reflects up-to-date information and has been reviewed and validated by subject matter experts working in the field.

thePoint features a question bank consisting of the pretest and post-test, offering more than 650 questions—two-thirds of them...

© 2016 BrightSurf.com